Summary:
- The article discusses the recent approval by the Central Drugs Standard Control Organization (CDSCO) for the clinical trial of a novel indigenous mRNA-based vaccine candidate (HGCO5) targeting the Omicron variant of SARS-CoV-2.
- It highlights the development efforts of Gennova Biopharmaceuticals, emphasizing the utilization of a thermostable platform that maintains vaccine efficacy at room temperature, which is a significant advancement for logistics and distribution in tropical climates.